Contribution of Sympathetic Nervous System Activity during Administration of Carvedilol in Rats with Dilated Cardiomyopathy

Summary: We investigated the contribution of the sympathetic nervous system (SNS) in maintaining blood pressure during administration of carvedilol in rats with dilated cardiomyopathy, and examined whether SNS hyperactivity induced by high‐dose carvedilol is related to severity of heart failure. The hypotensive effect of carvedilol in rats with heart failure (Group F) was not significantly different to that in rats without (Group N). However, enhancement of the plasma norepinephrine concentration during carvedilol administration in Group F was higher than in Group N. The constitutive plasma NE concentration in Group F (562 ± 146 pg/ml) was significantly higher than in Group N (203 ± 55 pg/ml) and there was a significant positive correlation between the heart weight to body weight ratio and the plasma norepinephrine concentration. Values for the maximal effect of the norepinephrine hypertensive effect during norepinephrine intravenous infusion (Emax) decreased, and plasma norepinephrine concentrations at half‐maximal effect of the norepinephrine hypertensive effect (EC50) increased in Group F compared with Group N (20.8 ± 6.1 and 28.6 ± 2.2 mmHg, and 4.5 ± 1.9 and 1.5 ± 0.2 ng/ml, respectively). These results suggested that the number of receptors (Emax) and sensitivity (EC50) to the norepinephrine hypertensive effect decreased in Group F. Changes in these parameters in Group F corresponded with the results of a &bgr;‐adrenergic receptor binding assay using I‐125 iodocyanopindolol (Bmax = 32 ± 4 in Group F and 53 ± 2 fmol/mg protein in Group N). These results showed that the SNS (presynaptic) activity increased and the SNS receptor sensitivity in the blood pressure regulation system decreased in heart failure. Therefore, high‐dose carvedilol treatment should be used with caution to avoid worsening heart failure.

[1]  Kenichi Watanabe,et al.  Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy , 2000, British journal of pharmacology.

[2]  ICHAEL,et al.  THE EFFECT OF CARVEDILOL ON MORBIDITY AND MORTALITY IN PATIENTS WITH CHRONIC HEART FAILURE , 2000 .

[3]  P. Lauriola,et al.  Avoidable deaths from vehicle accidents in Modena, Italy , 1998, The Lancet.

[4]  M Danhof,et al.  Pharmacokinetic-pharmacodynamic characterization of the cardiovascular, hypnotic, EEG and ventilatory responses to dexmedetomidine in the rat. , 1997, The Journal of pharmacology and experimental therapeutics.

[5]  H. Homma,et al.  Comparison of the sympathetic nervous system activity between spontaneously hypertensive and Wistar-Kyoto rats to respond to blood pressure reduction. , 1997, Biological & pharmaceutical bulletin.

[6]  R. Doughty,et al.  Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. , 1997, European heart journal.

[7]  Australia. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease , 1997, The Lancet.

[8]  G. Feuerstein,et al.  Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. , 1995, European heart journal.

[9]  A. Koshiro,et al.  Pharmacokinetic and pharmacodynamic studies of L-dopa in rats. I. Pharmacokinetic analysis of L-dopa in rat plasma and striatum. , 1994, Biological & pharmaceutical bulletin.

[10]  M. Kodama,et al.  Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. , 1994, Circulation research.

[11]  T. Santa,et al.  Relation between blood pressure and plasma catecholamine concentration after administration of calcium antagonists to rats. , 1994, Biological & pharmaceutical bulletin.

[12]  D. Goldstein,et al.  Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. , 1994, Journal of chromatography. B, Biomedical applications.

[13]  A. Shibata,et al.  Alterations of binding characteristics of alpha 1-,beta 1-adrenoceptors and Ca2+ binding sites in the myocardium of spontaneously hypertensive rats (SHR) by chronically administered bunazosin, atenolol, ketanserin and verapamil. , 1993, Biological & pharmaceutical bulletin.

[14]  E. Varnauskas,et al.  Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. , 1975, British heart journal.